Edition:
United Kingdom

Applied Genetic Technologies Corp (AGTC.OQ)

AGTC.OQ on NASDAQ Stock Exchange Global Market

4.70USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$4.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
19,246
52-wk High
$6.03
52-wk Low
$3.28

Select another date:

Wed, Apr 18 2018

BRIEF-AGTC Doses First Patient In Phase 1/2 Clinical Study Of Gene Therapy For Treatment Of X-Linked Retinitis Pigmentosa

* AGTC DOSES FIRST PATIENT IN PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR TREATMENT OF X-LINKED RETINITIS PIGMENTOSA Source text for Eikon: Further company coverage:

BRIEF-Applied Genetic Technologies Reports Quarterly Loss Per Share Of ‍$ 0.29​

* ‍APPLIED GENETIC TECHNOLOGIES QTRLY REVENUE $4.9 MILLION VERSUS $10.9 MILLION

BRIEF-Applied Genetic Technologies Reports Qtrly Loss Per Share Of ‍$0.29​

* ‍AS OF DECEMBER 31, 2017, COMPANY'S CASH, CASH EQUIVALENTS, AND INVESTMENTS AMOUNTED TO $119.7 MILLION​

BRIEF-Applied Genetic posts qtrly ‍net loss of $0.08​ per share

* Company expects total cash, cash equivalents, and investments as of june 30, 2018 to be between $85 and $100 million​

Select another date: